Actionable news
0
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR)

SANTA MONICA, Calif., April 15, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced the schedule of presentations and addresses related to its engineered cell therapy programs at the upcoming AACR Annual Meeting in New Orleans, Louisiana. Topics will include KTE-C19, Kite's lead chimeric antigen receptor (CAR) product candidate, as well as engineered T cell receptor (TCR) product candidates targeting solid tumors that express the MAGE-A3 and KRAS cancer proteins. KTE-C19 is currently being studied in four pivotal clinical trials. Clinical study of the MAGE-A3 TCR and pre-clinical study of KRAS TCRs are being advanced as part of a Cooperative Research and Development Agreement (CRADA) between Kite and the National Cancer Institute.

Oral Presentations

Updated Phase 1 Results from ZUMA-1: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Date: April 19, 2016, 4:00 - 4:15PM Central Time
Session: Early Clinical Trials Evaluating Cell-based, Checkpoint Inhibitors, and Novel Immunotherapeutics
Abstract Number: CT135
Location: Room 343, Morial Convention Center
Presenter: Armin Ghobadi, M.D., Washington University, St. Louis, MO

A Phase 1 Study of an HLA-DPB1*0401-restricted T Cell Receptor Targeting MAGE-A3 for Patients with Metastatic Cancer
Date: April 17, 2016, 3:15 - 3:35PM Central Time
Session: Immuno-Oncology Clinical Trials I
Abstract Number: CT003
Location: La Nouvelle Orleans Ballroom, Morial Convention Center
Presenter: Yong-Chen W. Lu, Ph.D., Surgery Branch, National Cancer Institute

Session Presentations

Plenary Session: T Cell Recognition of Human Cancer
Date: April 17, 2016, 11:00 - 11:30AM Central Time
Session: PL01 Opening Plenary - Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Location: Hall F, Morial Convention Center
Speaker: Ton Schumacher, Ph.D., Netherlands Cancer...


More